Midatech Pharma PLC Announces Exercise of Warrants and Issue of Equity

Rhea-AI Summary

Midatech Pharma PLC (AIM:MTPH; NASDAQ:MTP) has announced the issuance of 61,363 American Depositary Shares (ADSs), equating to 306,815 new ordinary shares, following the exercise of warrants by US investors at $2.0625 each. The company raised gross proceeds of $126,561. Admission of the new shares to the AIM Market of the London Stock Exchange is expected on or around February 19, 2021. Following this issuance, the total number of ordinary shares will be 63,380,667. The new shares will rank equally with existing shares.

Positive

• Gross proceeds of $126,561 from the warrant exercise.
• Increased total issued share capital to 63,380,667 shares.

Negative

• None.

ABINGDON, OXFORDSHIRE / ACCESSWIRE / February 17, 2021 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it has issued to certain US investors 61,363 American Depositary Shares ("ADSs"), representing 306,815 ordinary shares of 0.1p each in the Company ("New Ordinary Shares"), in connection with the exercise of pre-existing warrants by such investors at an exercise price of $2.0625 per ADS. Each ADS represents five ordinary shares. The gross proceeds received by the Company from the exercise of these warrants is $126,561.

Application has been made for admission of 306,815 New Ordinary Shares to trading on the AIM Market of the London Stock Exchange ("Admission"), which is expected to become effective at 8.00am on or around 19 February 2021. The New Ordinary Shares will rank pari passu with the existing ordinary shares.

The Company's issued share capital following the issue of equity noted above, will comprise 63,380,667 Ordinary Shares each with voting rights. The Company does not hold any shares in treasury. This figure of 63,380,667 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For more information, please contact:
Midatech Pharma PLC
Stephen Stamp, CEO, CFO
Tel: +44 (0)1235 888300
www.midatechpharma.com

Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker)
Freddy Crossley, Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)
Tel: +44 (0)20 7886 2500

Turner Pope Investments (TPI) Limited (Joint Broker)
Andrew Thacker (Corporate Broking)
Tel: +44(0)20 3657 0050

IFC Advisory Limited (Financial PR and UK Investor Relations)
Tim Metcalfe / Graham Herring
Tel: +44 (0)20 3934 6630
Email: midatech@investor-focus.co.uk

Edison Group (US Investor Relations)
Megan Paul
Tel: (646) 653 7034
Email: mpaul@edisongroup.com

About Midatech Pharma PLC
Midatech Pharma PLC (dual listed on LSE AIM:MTPH; and NASDAQ:MTP) is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The Company combines approved and development medications with its proprietary and innovative drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.

The Company has developed three in-house technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform:

• Q-Sphera™ platform: a disruptive micro-technology used for sustained release to prolong and control the release of therapeutics over an extended period of time (from weeks to months).
• MidaSolve™ platform: an innovative nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours.
• MidaCore™ platform: a leading-edge nanotechnology used for targeting medications to sites of disease.

The platform nature of the technologies offers the potential to develop multiple drug assets rather than being reliant on a limited number of programmes. Midatech's technologies are supported by 36 patent families including 120 granted patents and an additional 70 patent applications. Midatech's headquarters and R&D facility is in Cardiff, UK. For more information please visit www.midatechpharma.com

Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States Private Securities Litigation Reform Act. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements.

Reference should be made to those documents that Midatech shall file from time to time or announcements that may be made by Midatech in accordance with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Midatech are expressly qualified in their entirety by the cautionary statements above. Except as may be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, Midatech does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise arising.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Midatech Pharma PLC

View source version on accesswire.com:
https://www.accesswire.com/630163/Midatech-Pharma-PLC-Announces-Exercise-of-Warrants-and-Issue-of-Equity

FAQ

What did Midatech Pharma announce on February 17, 2021?

Midatech Pharma announced the exercise of warrants resulting in the issuance of 61,363 ADSs, totaling 306,815 ordinary shares.

How much did Midatech Pharma raise from the exercise of warrants?

Midatech Pharma raised gross proceeds of $126,561 from the exercise of warrants.

When will the new ordinary shares be admitted to trading?

The new ordinary shares are expected to be admitted to trading on February 19, 2021.

What is the total number of ordinary shares after the new issuance?

After the issuance, the total number of ordinary shares will be 63,380,667.

What is the exercise price for the warrants exercised by investors?

The exercise price for the warrants was $2.0625 per ADS.